- Home
- RAND vs PSTV Comparison
RAND vs PSTV Comparison
Compare RAND & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | PSTV |
|---|---|---|
| Founded | 1969 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 27.9M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RAND | PSTV |
|---|---|---|
| Price | $10.90 | $5.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 3.5K | ★ 3.8M |
| Earning Date | 05-04-2026 | 05-29-2026 |
| Dividend Yield | ★ 10.87% | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | $21.93 |
| Revenue Next Year | N/A | $279.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.05 | $0.13 |
| 52 Week High | $21.30 | $6.03 |
Technical Indicators
Market Signals| Indicator | RAND | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 86.55 |
| Support Level | $10.53 | $0.37 |
| Resistance Level | $11.15 | N/A |
| Average True Range (ATR) | 0.31 | 0.51 |
| MACD | -0.10 | 0.44 |
| Stochastic Oscillator | 19.46 | 87.33 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).